Cullinan Therapeutics Chief Scientific Officer Jennifer Michaelson Reports Sale of $49,440 in Common Shares
Bitget2026/11/06 22:01- Cullinan Therapeutics Chief Scientific Officer Jennifer Michaelson sold 4,000 common shares at $12.36 each on November 5, 2026.
- She also exercised stock options for 3,805 common shares at $4.3 each that day.
- Following the transactions, Michaelson directly held 158,649 common shares and 75,182 stock options.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like

Jensen Huang's influence surpasses that of Nvidia— and that's exactly the problem
Jensen Huang has been the key driving force behind the massive expansion of AI infrastructure, with his personal credibility and authoritative decision-making deeply embedded in the narrative of the global tech market’s rise over the past three years. Now, as scandals emerge, Nvidia’s trading team is expected to become more conservative and slow down external financing commitments, which undoubtedly worsens the situation for neoclouds already facing tight funding.


Deutsche Bank made significant Q3 purchases of midstream AI application stocks: the three major cloud giants saw increased holdings, with Palantir (PLTR.US) and Salesforce (CRM.US) also favored.
Deutsche Bank has submitted its third quarter 13F holdings report for the period ending September 30, 2026.
